To direct the Secretary of Health and Human Services to review utilization of diabetes screening benefits and make recommendations on outreach programs with respect to such benefits, and for other purposes.

H.R. 6012 ADA support the entire bill, which reviews the uptake and utilization of diabetes screening benefits and establish an outreach program with respect to such benefits (Lobbyist Used: Tekisha Dwan Everette, Meghan Riley)

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE

HR 2425/S 3211 - Medicare Diabetes Self Management Training Act H.R. 6012 - the Diabetes Screening Utilization Act H.R. 1995 - the Diabetes in Minority Communities Evaluation Act H.R. 5354 - the Gestational Diabetes Act (GEDI)

Client expense: $90,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 4899-provisions relating to pharmaceuticals; H.R. 4213-provisions relating to pharmaceutical pricing; H.R. 6012-utilization of Medicare diabetes screening benefit.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 1473/H.R. 1402, H.R. 6012 S. 1473/H.R. 1402, Catalyst to Better Diabetes Care Act of 2009 ADA supports the entire bill to change the care and treatment of diabetes in the US. Part of this bill was included in the Patient Protection and Affordable Care Act, and the ADA will continue to work to get the remainder of the bill passed. (Lobbyist Used: Kathryn Murray) H.R. 6012 ADA support the entire bill, which reviews the uptake and utilization of diabetes screening benefits and establish an outreach program with respect to such benefits (Lobbyist Used: Kathryn Murray, Tekisha Dwan Everette)

Client expense: $165,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

H.R. 1402 Catalyst to Better Diabetes Care Act of 2009 S. 1473 Catalyst to Better Diabetes Care Act of 2009 H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2010 S. 844 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009 H.R. 2590 Preventing Diabetes in Medicare Act of 2009 Obesity/Diabetes Issues P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 H.R. 6012 To direct the Secretary of Health and Human Services to review utilization of diabetes screening benefits and make recommendations on outreach programs with respect to such benefits, and for other purposes

Client expense: Not reported · Firm income: $60,000

P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 H.R. 6012 To direct the Secretary of Health and Human Services to review utilization of diabetes screening benefits and make recommendations on outreach programs with respect to such benefits, and for other purposes H.R. 1995 Diabetes in Minority Populations Evaluation Act of 2010 H.R. 5354 Gestational Diabetes Act of 2010 S. 3397 Secure and Responsible Drug Disposal Act of 2010 S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Diabetes Related Provisions) H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) H.R. 1359 Secure and Responsible Drug Disposal Act of 2009

Client expense: Not reported · Firm income: $60,000

Comparative Effectiveness Medicare Issues P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals S. Amdt. (Baucus) to H.R. 4849 Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions) H.R. 1586 Education Jobs and Medicaid Funding Bill (AMP Revisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions) H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision) H.R. 6012 To direct the Secretary of Health and Human Services to review utilization of diabetes screening benefits and make recommendations on outreach programs with respect to such benefits, and for other purposes H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)

Client expense: Not reported · Firm income: $60,000

HR 6012 - To direct the Secretary of Health and Human Services to review uptake and utilization of diabetes screening benefits and establish an outreach program with respect to such benefits, and for other purposes. HR 2891 - Access to Frontline Health Care Act of 2009 Under Line 17: We would like to include the Agency for Healthcare Research and Quality (AHRQ) HR 2345 - Amends the Fair Credit Reporting Act to provide for an exclusion from Red Flag Guidelines for health care practices HR 1259 - Dextromethorphan Distribution Act of 2009 Drug Safety Discussion Draft Bill (builds on the Food and Drug Globalization Act - HR 759) - Amends the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, and for other purposes. (Public Law 111-152) Health Care and Education Reconciliation Act of 2010 [Sections on Medicare Part D Changes; CMS/IRS data match to identify fraudulent providers; funding to fight fraud, waste and abuse; 90-day period of enhanced oversight for initial claims of DME suppliers; excise tax on medical device manufacturers; and drugs purchased by covered entities.] (Public Law 111-148) - Patient Protection and Affordable Care Act [Sections on: reinsurance for early retirees; non-discrimination in health care; essential health benefits requirements; financial integrity in Exchanges; MedPAC study on adequacy of Medicare payments for health care providers serving in rural areas; coverage of comprehensive tobacco cessation services for pregnant women in Medicaid; distributions for medicine qualified only if for prescribed drug or insulin; administrative simplification; payment for biosimilar biological products; approval pathway for biosimilar biological products; patient-centered outcomes research; special rules; prohibition against discrimination on assisted suicide; presentation of prescription drug benefit and risk information; provider screening and other enrollment requirements under Medicare, Medicaid, and CHIP; enhanced Medicare and Medicaid program integrity provisions; maximum period for submission of Medicare claims reduced to not more than 12 months; physicians who order items or services required to be Medicare enrolled physicians or eligible professionals; requirement for physicians to provide documentation on referrals to programs at high risk of waste and abuse; face to face encounter with patient required before physicians may certify eligibility for home health services or durable medical equipment under Medicare; enhanced penalties; adjustments to the Medicare durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) competitive acquisition program; termination of provider participation under Medicaid if terminated under Medicare or other State plan; Medicaid exclusion from participation relating to certain ownership, control, and management affiliations; health information technology enrollment standards and protocols; improvements to the physician quality reporting system; hospital readmissions reduction program; community-based care transitions program; Medicare Advantage payment; demostration project to evaluate integrated care around a hospitalization; state option to provide health homes for enrollees with chronic conditions; pediatric accountable care organization demonstration project; establishment of Center for Medicare and Medicaid Innovation within CMS; Medicare shared savings program; national pilot program on payment bundling; independence at home demonstration program; establishing community health teams to support the patient-centered medical home; Medicaid coverage for the lowest income populations; elimination of exclusion of coverage of certain drugs; providing adequate pharmacy reimbursement (AMP); improvements to the Medicare Part D MTM programs; exemption of certain pharmacies from DMEPOS accreditation requirements; payment adjustments for home health care; Medicare coverage gap discount program; immediate reduction in coverage Medicare Part D gap in 2010; improved information for subsidy eligible individuals reassigned to prescription drug plans and MA-PD plans; improving formulary requirements for prescription drug plans and MA-PD plans with respect to certain categories or classes of drugs; elimination of cost sharing for certain dual eligible individuals; uniform exceptions and appeals process for prescription drug plans and MA-PD plans; Office of the Inspector General studies and reports; including costs incurred by AIDS drug assistance programs and Indian Health Service in providing prescription drugs toward the annual out-of-pocket threshold under part D; reducing wasteful dispensing of outpatient prescription drugs in long-term care facilities under prescription drug plans and MA-PD plans; medication management (MTM) services in treatment of chronic disease; advancing research and treatment for pain care management; National Prevention, Health Promotion and Public Health Council; clinical and community preventive services; Medicare coverage of annual wellness visit providing a personalized prevention plan; removal of barriers to preventive services in Medicare; incentives for prevention of chronic diseases in Medicaid; community transformation grants; healthy aging, living well - evaluation of community-based prevention and wellness programs for Medicare beneficiaries; CDC and employer-based wellness programs; coverage of preventive health services; immunizations; community health insurance option; level playing field; State flexibility to establish basic health programs for low-income individuals not eligible for Medicaid; ensuring the quality of care; affordable choices of health benefit plans; national strategy to improve health care quality; interagency Working Group on Health Care Quality; quality measure development; quality measurement; data collection; public reporting; health care delivery system research; quality improvement technical assistance; demonstration program to integrate quality improvement and patient safety training into clinical education of health professionals; transparency reports and reporting of physician ownership or investment interests; prescription drug sample transparency; pharmacy benefit managers transparency requirements; national health care workforce commission; health care workforce assessment; public health workforce recruitment and retention programs; allied health workforce recruitment and retention programs; grants for State and local programs; training in family medicine, general internal medicine, general pediatrics, and physician assistantship; geriatric education and training: career awards, comprehensive geriatric education; United States Public Health Sciences Track; interdisciplinary, community-based linkages (to support the existing health care workforce); Medicare vaccine coverage issues (Medicare Part B vs. Part D); nominations to National Health Care Workforce Commission and Board of Governors of the Patient-Centered Outcomes Research (PCOR) Institute; and funding for the grant program established in the section on medication management (MTM) services in treatment of chronic disease).] (26 CFR Part 54/ 29 CFR Part 2590/ 45 CFR Parts 146 and 148) Medical Loss Ratios; Request for Comments Regarding Section 2718 of the Public Health Service Act (Docket Number: OCIIO-9992-IFC) Interim Final Rules for Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient Protection and Affordable Care Act (RIN 0991-AB62) HIPAA Privacy Rule Accounting of Disclosures Under the Health Information Technology for Economic and Clinical Health Act; Request for Information (RIN 0991AB57) Modifications to the HIPAA Privacy, Security, and Enforcement Rules Under the Health Information Technology for Economic and Clinical Health Act (Docket Number: FDA-2010-D-0431) Draft Guidance for Food and Drug Administration Staff and Tobacco Retailers on Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers; Availability (Docket Number: FDA-2010-N-0449) Risks and Benefits of Long-Term Use of Nicotine Replacement Therapy Products; Public Workshop; Request for Comments FDA Draft Guidance for Industry Tobacco Retailer Training Programs NAIC Regulation for Uniform Definitions and Standardized Rebate Calculation Methodology for Plan Years 2011, 2012 and 2013 per Section 2718 (b) of the Health Service Act HHS National Health Care Quality Strategy and Plan Draft Report of the HHS Secretarys Advisory Committee on Genetics, Health, and Society on Genetics Education and Training of Health Care Professionals, Public Health Providers, and Consumers Concept Opportunities for Pharmacist Clinical Services in Health Care Reform Provisions

HR 2425/S 3211 - Medicare Diabetes Self Management Training Act H.R. 6012 - the Diabetes Screening Utilization Act H.R. 1995 - the Diabetes in Minority Communities Evaluation Act H.R. 5354 - the Gestational Diabetes Act (GEDI)

Client expense: $90,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE